Labcorp (LH) Projected to Post Quarterly Earnings on Wednesday

Labcorp (NYSE:LH) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Labcorp to post earnings of $4.64 per share and revenue of $3.76 billion for the quarter. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same period last year, the firm posted $4.35 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. On average, analysts expect Labcorp to post $18.32 EPS for the current fiscal year and $19.69 EPS for the next fiscal year.

Labcorp Price Performance

NYSE LH opened at $329.10 on Monday. Labcorp has a 12 month low of $244.52 and a 12 month high of $341.80. The firm has a market capitalization of $26.69 billion, a PE ratio of 27.22, a P/E/G ratio of 1.88 and a beta of 0.87. The company’s 50 day simple moving average is $320.94 and its 200 day simple moving average is $291.11. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio (DPR) is presently 23.82%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LH shares. Bank of America lifted their price target on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $306.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Weiss Ratings upgraded Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday. Barclays raised their target price on Labcorp from $320.00 to $330.00 and gave the company an “equal weight” rating in a research note on Friday, September 11th. Finally, Truist Financial lifted their target price on Labcorp from $350.00 to $365.00 and gave the stock a “buy” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.

Insider Activity at Labcorp

In other Labcorp news, EVP Amy B. Summy sold 924 shares of Labcorp stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. The trade was a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kerrii B. Anderson sold 3,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares in the company, valued at $2,087,165.26. This represents a 31.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,593 shares of company stock valued at $2,733,295 over the last ninety days. Insiders own 0.84% of the company’s stock.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.